6-Methylquinazolin-4(3H)-one Based Compounds as BRD9 Epigenetic Reader Binders: A Rational Combination of in silico Studies and Chemical Synthesis

被引:9
作者
Colarusso, Ester [1 ]
Gazzillo, Erica [1 ,2 ]
Boccia, Eleonora [1 ,2 ]
Giordano, Assunta [1 ,3 ]
Chini, Maria Giovanna [4 ]
Bifulco, Giuseppe [1 ]
Lauro, Gianluigi [1 ]
机构
[1] Univ Salerno, Dept Pharm, Via Giovanni Paolo II 132, I-84084 Fisciano, SA, Italy
[2] Univ Salerno, PhD Program Drug Discovery & Dev, Via Giovanni Paolo II 132, I-84084 Fisciano, SA, Italy
[3] Consiglio Nazl Ric CNR, Inst Biomol Chem ICB, Via Campi Flegrei 34, I-80078 Pozzuoli, NA, Italy
[4] Univ Molise, Dept Biosci & Terr, I-86090 Pesche, IS, Italy
关键词
Antitumor agents; Combinatorial chemistry; Cyclization; Drug design; Structure-activity relationships; CASCADE SYNTHESIS; ACCURATE DOCKING; BROMODOMAIN; GLIDE; QUINAZOLIN-4(3H)-ONES; DESIGN; PHASE; MODEL;
D O I
10.1002/ejoc.202200868
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
6-methylquinazolin-4(3H)-one-based compounds were here identified and synthesized as novel binders of bromodomain-containing protein 9 (BRD9) epigenetic reader. Accounting a fast and efficient synthetic route aimed to easily obtain differently 2- and 8-disubstituted 6-methylquinazolin-4(3H)-one derivatives, a virtual library of synthesizable items was built and submitted to molecular docking experiments. Based on two 3D structure-based pharmacophore models recently developed by us on BRD9, 16 compounds were selected and synthesized, using mild conditions with good yields in relatively short reaction times. Among them, 14, 16, 18, 22, and 26 emerged as the most potent compounds of these series, able to bind BRD9 at the low micromolar range of concentrations. These molecules also showed a promising selective behavior when tested against BRD4 bromodomain. These results highlighted the quinazolin-4(3H)-one chemical core as a valuable scaffold for developing promising BRD9 binders.
引用
收藏
页数:10
相关论文
共 36 条
[31]   A new approach to the facile synthesis of mono- and disubstituted quinazolin-4(3H)-ones under solvent-free conditions [J].
Salehi, P ;
Dabiri, M ;
Zolfigol, MA ;
Baghbanzadeh, M .
TETRAHEDRON LETTERS, 2005, 46 (41) :7051-7053
[32]   Insight into selective mechanism of class of I-BRD9 inhibitors toward BRD9 based on molecular dynamics simulations [J].
Su, Jing ;
Liu, Xinguo ;
Zhang, Shaolong ;
Yan, Fangfang ;
Zhang, Qinggang ;
Chen, Jianzhong .
CHEMICAL BIOLOGY & DRUG DESIGN, 2019, 93 (02) :163-176
[34]   Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition [J].
Theodoulou, Natalie H. ;
Bamborough, Paul ;
Bannister, Andrew J. ;
Becher, Isabelle ;
Bit, Rino A. ;
Che, Ka Hing ;
Chung, Chun-wa ;
Dittmann, Antje ;
Drewes, Gerard ;
Drewry, David H. ;
Gordon, Laurie ;
Grandi, Paola ;
Leveridge, Melanie ;
Lindon, Matthew ;
Michon, Anne-Marie ;
Molnar, Judit ;
Robson, Samuel C. ;
Tomkinson, Nicholas C. O. ;
Kouzarides, Tony ;
Prinjha, Rab K. ;
Humphreys, Philip G. .
JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (04) :1425-1439
[35]   SYNTHESIS AND ANTICONVULSANT ACTIVITY OF SOME NEW 2-SUBSTITUTED 3-ARYL-4(3H)-QUINAZOLINONES [J].
WOLFE, JF ;
RATHMAN, TL ;
SLEEVI, MC ;
CAMPBELL, JA ;
GREENWOOD, TD .
JOURNAL OF MEDICINAL CHEMISTRY, 1990, 33 (01) :161-166
[36]   Targeting BRD9 for Cancer Treatment: A New Strategy [J].
Zhu, Xiuzuo ;
Liao, Yi ;
Tang, Liling .
ONCOTARGETS AND THERAPY, 2020, 13 :13191-13200